发明名称 Oncolytic vaccinia virus cancer therapy
摘要 Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.
申请公布号 US9226977(B2) 申请公布日期 2016.01.05
申请号 US201514656397 申请日期 2015.03.12
申请人 SillaJen Biotherapeutics, Inc. 发明人 Kirn David
分类号 A61K48/00;A61K9/00;A61K38/19;A61K45/06;A61K35/768 主分类号 A61K48/00
代理机构 Morgan, Lewis & Bockius LLP 代理人 Morgan, Lewis & Bockius LLP
主权项 1. A method of inducing oncolysis in a human subject having a tumor comprising administering to said subject one or more single doses of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified TK-deficient, human GM-CSF-expressing, replication-competent vaccinia virus vector wherein said single dose comprises 1×109 pfu to 1×1010 pfu, and wherein said administering comprises injection into the tumor mass, whereby oncolysis is induced in said tumor and in at least one tumor that is not injected with the virus.
地址 San Francisco CA US